Pertuzumab
CAS 380610-27-5 2 FDA-DMF suppliersBiologic
Overview
Pertuzumab is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic breast cancer. It works by targeting and inhibiting the HER2 receptor, which is overexpressed in some breast cancer cells.
Therapeutic areas
OncologyBreast Cancer Treatment
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.